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Objective: This study evaluated longitudinal trends in abdominal aortic aneurysm (AAA) management after later-
generation endografts became available.
Methods: We retrospectively analyzed non-suprarenal AAA repairs between January 1, 1996, and December 31, 2008,
performed at a single institution. Patients were stratified by endovascular AAA repair (EVAR) or open repair and the
presence or absence of rupture. Thirty-day mortality rates were compared with the Fisher exact test.
Results: During a 13-year period, 721 patients underwent AAA repair, comprising 410 (56.9%) with EVAR and 311
(43.1%) with open repair. A bimodal distribution of EVAR usage was observed, with initial escalation in the 1990s to
70%. A nadir of EVAR occurred in the early 2000s (40%), correlating with more conservative EVAR use after the
limitations of first-generation endografts were understood. Between 2005 and 2008, average EVARuse increased to 84%.
The overall 30-daymortality rate for the entire cohort, including ruptured AAA, was 3.8%: 2.0% (8 of 410) for EVAR and
6.1% (19 of 311) for open repair (P< .05). Ruptured AAA had a mortality rate of 0% (0 of 8) for EVAR vs 31% (9 of 29)
for open (P .16). Non-ruptured AAAmortality was 2.0% (8 of 402) for EVAR vs 3.6% (10 of 282) for open (P .23).
EVAR and open repair both had reductions in mortality in the latter half of the series, combining to provide a significant
decrease in overall mortality to 1.8% for patients treated from 2003 to 2008 compared with 4.9% for 1996 to 2002 (P<
.05). Open AAA repair became more complex during the study period. The average rate for juxtarenal open AAA repair
was 17.7% (range, 6.5%-34.6%) between 1996 and 2002 compared with 55.6% (range, 29.6%-100%) between 2003 and
2008 (P < .05).
Conclusions: AAA treatment has undergone a profound and sustained paradigm shift, now averaging 84% of repairs
performedwith EVARbetween 2005 and 2008. Overall mortality fromAAA repair, including ruptures, was reduced 64%
(from 4.9% to 1.8%) during the 13-year study period. Although EVAR and open repair both had improved mortality in
the latter half of the series, the primary driver in reduced mortality for AAA repair has been the shift to EVAR. (J Vasc
Surg 2010;51:1348-53.)New medical technology and procedures are frequently
embraced by the medical community before knowledge of
long-term results becomes available. Endovascular abdom-
inal aortic aneurysm (AAA) repair (EVAR) was one such
medical technology that may have had an initial “irrational
utilization.”1 We have observed a steady increase in the
endovascular repair of infrarenal AAAs since the first case
reported by Parodi in 19912 until midterm reports of
EVAR uttered a cautionary note in the early 2000s.3,4
Multiple problems or failure modes for EVAR have
been described, such as proximal endograft migration,5-7
endograft stent or hook fractures,8 fabric fatigue and mic-
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1348roleaks,9,10 late ruptures,11 and a significant incidence of
secondary procedures.12 Newer-generation endografts
were developed in response to these problems. The purpose
of this study was to examine the longitudinal trends of AAA
management during the last 13 years as endograft technol-
ogy was evaluated and incorporated into treatment algo-
rithms.
METHODS
We retrospectively analyzed a prospectively maintained
database of non-suprarenal AAA repairs between January 1,
1996, and December 31, 2008, at the Ochsner Clinic,
augmented with a retrospective review of medical records
and images. Part of this data set was previously published in
2003.1 Ochsner’s Institutional Review Board approval was
obtained. Patients were stratified by EVAR vs open repair
and presence or absence of rupture. Patients were evaluated
before surgery with contrast-enhanced computed tomog-
raphy (CT) unless severe renal insufficiency (creatinine
1.8 mg/dL) was present. Selective use of angiography
occurred early in this series.
In this analysis, three categories comprised non-suprarenal
AAA: (1) infrarenal AAA was defined by placement of the
aortic clamp infrarenally, (2) juxtarenal inferred need for
suprarenal/supraceliac aortic clamping, and (3) the pararenal
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placement and renal artery reimplantation or bypass. Open
repairs that involved endograft extraction or pararenal,
suprarenal, and thoracoabdominal aneurysms were ex-
cluded from this review. Endovascular repair was accom-
plished with Ancure/EVT (Guidant, Menlo Park, Calif),
AneuRx (Medtronic, Minneapolis, Minn), Excluder (W. L.
Gore, Flagstaff, Ariz), Talent (Medtronic), and Zenith
(Cook, Bloomington, Ind) endografts. Open AAA repairs,
for which Dacron grafts were used almost exclusively, were
generally performed through a transperitoneal incision
with liberal use of postoperative epidural catheters for pain
control.
Patient selection. The choice of EVAR vs open AAA
repair was individualized for each patient but was ultimately
made at the discretion of the staff vascular surgeon. There
was no single treatment decision algorithm. In the earlier
portion of the series, most patients undergoing EVAR were
part of Food and Drug Administration (FDA) pivotal stud-
ies and thus conformed to the anatomic instructions for use
(IFU). These included a minimum neck length of 10 mm in
the AneuRx trial and 15 mm in the Zenith trial. These
anatomic constraints and others (angulation, conical neck)
were liberalized in the latter half of the series.
Size threshold for repair did not change during the
series. Patients with AAA 5.0 to 5.5 cm were generally
offered repair if they were fit, anatomically suitable, and
aged 80 years old. Older patients were preferentially
offered EVAR, but at a larger size threshold. Lower size
thresholds (5 cm) for EVAR were never routinely
adopted in this series. Patients with rapidly expanding AAA,
(1 cm in 12 months), symptomatic or saccular aneurysms,
very young (60 years old) fit patients, or AAA in women
were selectively treated at a size between 4.5 and 4.9 cm.
We further analyzed results of two different periods
after the advent of third-generation endografts. Between
1996 and 2002, most EVARs were performed as part of
phase II or III of the FDA pivotal trials of the EVT/
Ancure, AneuRx, and Zenith endografts. Details regarding
selection criteria, anesthesia preference, conduct of opera-
tion, and measurement of aortic neck anatomy have been
previously published.5,13 After 2003, we also used Talent
and Excluder stent grafts, with most being the Zenith
Table. Age, abdominal aortic aneurysm (AAA) size, and
distribution in two study periods for endovascular aneurysm
Variable
1996-2002
EVAR Open
Number 200 244
Age, mean  SD, y 73.2  7.3 70.6  8.1
AAA size, mean  SD, cm 5.65  1.13 6.03  1.2
ASA 2, % 4.5 1.62
ASA 3, % 73 59.92
ASA 4, % 21.5 33.6
ASA 5, % 1 4.86device.Mortality rates at 30 days were compared with Fisher
exact test. Patient demographics and aneurysm characteris-
tics are reported as the mean  the standard deviation or
percentage.
RESULTS
Between 1996 and 2008, 721 patients underwent non-
suprarenal AAA repair: 410 (56.9%) underwent EVAR, and
311 (43.1%) underwent open repair. There were 37 (5.1%)
aneurysm repairs for rupture, 8 in the EVAR group and 29
for the open repair group. Men comprised 85.9% of the
EVAR group and 82.3% of open repair group. Age, AAA
size, and American Society of Anesthesiology (ASA) classi-
fication distribution are presented in the Table.
The patients in the EVAR group were older than the
open group (73.2 vs 70.6 years, P .01) in the first period,
but that difference disappeared in the second period. Pa-
tients undergoing open AAA repair had significantly larger
aneurysms than those undergoing EVAR in both periods
(Table). These differences were magnified during the latter
period between 2003 and 2008, when the mean size of
open AAA repair was 6.6 cm. The larger AAA size in the
open repair group may reflect the unfavorable aortic neck
more commonly associated with bigger aneurysms. There
was no difference in mean AAA size in the EVAR group
between the two periods studied (range, 5.5-5.6 cm),
confirming that we did not change our AAA size indication
for EVAR. Most patients in the study were in ASA classifi-
cation 3 and 4 in both periods (94.5% EVAR, 92.98% open;
and 85.4% EVAR, 86.9% open).
Of the endografts implanted, 391 (95.4%) were bifur-
cated; less common configurations included 5 aortouniiliac
endografts with femorofemoral bypass and 14 tube grafts
for saccular AAAs or aortic pseudoaneurysms. Endovascu-
lar repair was accomplished with 14 Ancure/EVT, 130
AneuRx, 20 Excluder, 2 Talent, and 244 Zenith en-
dografts. Distribution of endografts in both periods is
shown in Figs 1 and 2.
Treatment type. A bimodal distribution of EVAR
usage was observed (Fig 3), with initial escalation in the late
1990s. A nadir of EVAR usage occurred in the early 2000s,
correlating with more conservative EVAR use after the
limitations of first-generation endografts were better un-
rican Society of Anesthesiologist (ASA) classification
air (EVAR) and open AAA repair groups
2003-2008
P value EVAR Open P value
210 67
.01 73.7  8.5 72.9  9.0 .5
.01 5.54  1.22 6.64  1.95 .01
.14 13.2 2.9 .05
.01 65.9 71 .45
.01 19.5 15.9 .7
.05 1.5 10.1 .01Ame
rep
3derstood. EVAR use increased to an average rate of 77%
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became available. When 2003 and 2004 were excluded, the
mean EVAR use between 2005 and 2008 was 84%. This
compared with an average rate of 42.2% (range, 20.5%-
68.7%) between 1996 and 2002 (P  .05).
During the last 4 years of this review (2005-2008), 146
EVARs were performed with a mean follow-up of 15.9 
11.6 months. Of these, 30 (20.5%) EVARs were for AAAs
with disadvantaged necks that were outside the anatomic
IFU. During this period, there was an 8.2% (12 of 146) use
of giant Palmaz stents at the initial implant to successfully
treat intraoperative type 1a endoleaks that did not respond
to angioplasty. No fenestrated devices, chimney tech-
niques, or operative debranching was used. Secondary in-
terventions were required in 15 patients (10.3%) in this
cohort.
We observed a greater complexity for the open AAA
Fig 1. Endograft distribution in the period 1996 to 2002. Most
of the endografts used were AneuRx in the initial trials, followed by
the Zenith device.
Fig 2. Endograft distribution in the period 2003 to 2008. Most
of the endografts were the Zenith device, with a significant in-
creased use of the Excluder device and a substantial decreased use
of the AneuRx device.repair in the 2003 to 2008 period (Fig 4). The average ratefor juxtarenal open AAA repair was 17.7% (range, 6.5%-
34.6%) between 1996 and 2002 compared with 55.6%
(range, 29.6%-100%) between 2003 and 2008 (P  .05).
Mortality rate. The overall mortality rate for the en-
tire cohort (including ruptured AAA) was 3.8%: 2.0% (8 of
410) for EVAR and 6.1% (19 of 311) for open repair (P 
.05). Ruptured AAAs had a mortality rate of 0% (0 of 8) for
EVAR vs 31% (9 of 29) for open repair (P .16). Nonrup-
tured AAA mortality was 2.0% (8 of 402) for EVAR vs 4.8%
(10 of 282) for open repair (P  .23). When we analyzed
the mortality in the two periods, the mortality rate for
EVAR dropped from 3% (6 of 200) in the 1996-2002
period to 1% (2 of 210) in the 2003-2008 period (P .16).
The mortality rate for open AAA repair dropped from 6.5%
(16 of 244) in the 1996-2002 period to 4.5% (3 of 67) in
the 2003-2008 period (P  .77). There was a statistically
significant decrease in mortality for the entire cohort be-
tween the first (1996-2002) and second period (2003-
2008), 4.96% (22 of 444) vs 1.81% (5 of 277) respectively
Fig 3. The percentage of endovascular aneurysm repair use in the
study period significantly increased in the second period, averaging
77% between 2003 and 2008 (P  .05).
Fig 4. The percentage of juxtarenal abdominal aortic aneurysm
(AAA) in the open repair group in the study period significantly
increased in the second period (P  .05).(P  .05).
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A sustained paradigm shift in AAA repair technique was
observed during the study period. EVAR became dominant
during this 13-year period, with an average 84% use of
EVAR between 2005 and 2008. Increasingly, open repair
has been used for patients with very unfavorable anatomy
for EVAR. This trend was confirmed by the increased
percentage of juxtarenal AAA in the open AAA repair
group. Better endograft design has been a primary driver in
our increased use of EVAR. Incremental improvements in
fixation, delivery profile, fabric porosity, and sizing flexibil-
ity have all contributed to this trend.
We have also become more aggressive with treatment
of more challenging aortic neck anatomy. In our early
experience, most endografts were placed as part of phase
II/III FDA pivotal trials and thus had to conform to the
anatomic inclusion criteria included in the manufacturer’s
IFU. We have been increasingly comfortable in selectively
treating patients whose anatomy falls outside the IFU;
between 2005 and 2008, 20.5% of patients undergoing
EVAR had disadvantaged aortic neck anatomy. The ability
to use adjunctive techniques for securing a good proximal
seal, such as with “giant” Palmaz stent placement, has been
an important component in allowing the treatment of these
patients with disadvantaged aortic necks.14 Nearly 1 in 10
patients (8.2%) required a giant Palmaz stent between 2005
and 2008. Despite this aggressive stance, our need for
subsequent secondary procedures in this cohort (10.3%)
was comparable to prior publications.12
Patients who received open AAA repairs in recent prac-
tice universally had poor anatomy for EVAR. In the earlier
portion of this series, young patients were a bit more likely
to have open repair; however, this age bias has been largely
abandoned. If a patient has an excellent aortic neck (2 cm
length, not conical or angulated), even young patients will
preferentially be offered EVAR in current practice. How-
ever, a young healthy patient with marginal aortic neck
anatomy will be preferentially offered an open repair.
Unfavorable iliac anatomy has seldom been an imped-
iment to EVAR with the current lower-profile devices.
Although unilateral hypogastric embolization has been
used with some frequency,15 we have rarely chosen to
intentionally sacrifice both hypogastric arteries. We have
been more creative in order to preserve at least one hypo-
gastric artery, usually with endovascular approaches. Iso-
lated external to hypogastric bypasses were performed in
several patients in the first portion of the series. We have
occasionally performed open AAA repair in very active
patients with bilateral common iliac artery aneurysmal in-
volvement in whom significant buttock claudication would
have been very limiting.
Iliac conduits, which have been used very sparingly, can
also increase the percentage of EVAR use.16 Most adverse
iliac artery anatomy can be overcome with adjunctive tech-
niques and, assuming a successful implant, is less likely to
negatively affect long-term durability. This statement is not
true for adverse aortic neck anatomy, however. Althoughvery short and/or angulated necks can be “treated” with
EVAR, the long-term outcome of such a repair is far less
certain.17,18
Use of EVAR in the overall United States market has
demonstrated a steady increase, from 38% in 2001 to 72%
in 2006.19 Although our single-center use of EVAR was
much higher than the national average in the earlier part of
this series, our more recent EVAR use is not dissimilar to
national trends. Our early-adopter status was likely influ-
enced by access to endografts available only as part of
pivotal FDA trials. There may have also been a premature
rush to embrace new technology, an “endoexuberance.”1
EVAR has been demonstrated to have significantly
reduced perioperative morbidity and mortality than open
repair.20-22 Our single-center experience has corroborated
these findings. Interestingly, we have noted trends in con-
tinued improvement in mortality rates for EVAR (3.0% to
1.0%) and open repair (6.5% to 4.5%) between 1996-2002
and 2003-2008, respectively. Although these changes were
not statistically significant, the trends seem undeniable. The
reasons for these salutary changes are likely multifactorial.
Improvements in patient selection, endograft design, and
operator experience are the likely drivers of decreased mor-
tality in the EVAR group. The improvements in open AAA
mortality are somewhat surprising, because there was a
strong selection bias towards more difficult open cases in
the latter half of the series. Continued refinements in
anesthesia and perioperative management may have played
a role.
This sustained paradigm shift brings other concerns.
One of these issues is economic. The perioperative cost for
EVAR is significantly higher than open repair.23 When
costs of surveillance and needed secondary procedures over
a 5-year period are added, the global cost of EVAR in-
creases by approximately 50%.24 Changing the type and
frequency of surveillance in selected patients may offer
some cost-savings.25 However, secondary intervention,
which occurs in up to 20% of the EVAR patients when
followed-up for 5 years, is the primary driver of long-term
cost.24,26 To decrease the need for secondary intervention,
improvements in endograft technology need to continue.
Perhaps most importantly, better definition of patients who
will do better with EVAR or open AAA repair is needed.
There will be patients with unfavorable anatomy but at a
greater risk for open AAA repair that would benefit from
EVAR, despite the greater cost.27 Alternately, there are a
significant number of fit younger patients or those with
unfavorable anatomy that would do well with open AAA
repair28 at a much lesser cost.
CONCLUSION
AAA treatment has undergone a profound and sus-
tained paradigm shift, now averaging 84% of repairs per-
formed with EVAR between 2005 and 2008. Increasingly,
open repair has been used for patients with very unfavorable
anatomy for EVAR. This trend was confirmed by the
increased percentage of juxtarenal AAA repair in the open
group. The 30-day mortality was less with EVAR than with
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the past 5 years. Treatment of AAA has become safer, with
the overall mortality (including ruptures) reduced 64%
(from 4.9% to 1.8%) during the 13-year study period.
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Dr Ross Milner (Atlanta, Ga): As demonstrated in this
manuscript and this presentation, many centers have seen a dra-
matic change in the management of aneurysms. The results of the
DREAM [Dutch Randomised Endovascular Aneurysm Manage-
ment] and the EVAR-1 [Comparison of Endovascular Aneurysm
Repair with Open Repair in Patients with Abdominal Aortic An-significant difference in the perioperative mortality rates of endo-
vascular open repair that is three times in favor of endovascular
repair. In addition, reports by Dr Schermerhorn in the New
England Journal of Medicine have shown this perioperative mor-
tality rate difference to be true especially in older patients. The
initial mortality rate difference seems to go away a little bit over
time with both the DREAM and EVAR-1 trials, but this does not
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still remains a strong enthusiasm for endovascular repair.
Your paper is a very nice review of 13 years’ worth of experi-
ence of open and endovascular repair at a single institution, and the
main goal, as you said, was to demonstrate the rate of adoption.
And I know you highlighted some of the limitations and those are
some of the questions I am going to bring up.
The authors show a bimodal distribution of adoption with
an over 80% rate of AAAs [abdominal aortic aneurysms] being
treated in an endovascular fashion. You have shown that initially
there was some decrease in enthusiasm after the initial device
showed some concern for problems, and as the second-genera-
tion of devices have been introduced, a greater adoption of
endovascular repair. In your center, as you said, the majority
have been Zenith. I think around the country there is a different
distribution of devices depending on the center, but similar
widespread adoption of endovascular repair.
You show both a low mortality rate with both open and
endovascular repair. Your open mortality rate obviously was
higher, as would be expected, but included aneurysms that re-
quired both suprarenal and supraceliac clamping as well as renal
artery revascularizations. You show an improvement in outcomes in
all patients in your later period, and I think in addition you should be
congratulated for an overall low mortality rate with ruptures.
Major limitations of this work are that the authors do not include
any of the standard anatomic variables that we usually use to assess
candidacy for endovascular therapy as well as report on any endoleak
analysis that occurred perioperatively or long term.
So first of all, how many of your patients treated by EVAR had
adjuncts, such as placement of a Palmaz stent, performed during initial
device placement? Just to give us a better idea to understand how many
patients were appropriate candidates based on appropriate IFU [instruc-
tions for use] or how many people were using challenging anatomy that
you are trying to expand your indications for endograft therapy.
As mentioned above, and as you said in your presentation, there
is no endoleak data currently in this manuscript. I think it is very
important to document the endoleaks, especially with potentially type
I from neck issues considering your very widespread adoption of
endovascular therapy, because if there are long-term consequences of
rupture or aneurysm expansion, you may rethink the overall high rate
of use. So therefore, what is your endoleak rate in your series, your rate
of secondary interventions, and as a follow-up, are there any conver-
sions to open repair in your over 400 endografts that you placed?
One other concern is the use of endografts in younger pa-
tients. Have you looked at how you treat patients younger than 65
years old? Specifically, of patients younger than 65, how many were
treated by endografts, how many had open repair, and what is your
mortality rate in this selected group of patients?
And finally, I, as well as you, have a particular interest in the
complexity of open AAA repairs performed in tertiary medical
care centers with the widespread use of EVAR. The majority of
these open repairs, as you mentioned, require complex manage-
ment of the visceral segment of the aorta. You clearly described
three categories: The first is just an infrarenal clamp; the second
requires a suprarenal or supraceliac clamp; and the third one is
the same higher level of clamping but with renal artery revascu-
larizations. Have you looked at the different mortality rates in
these three groups, especially when you compare the difference
between the suprarenal or supraceliac clamping and renal artery
revascularizations, and is the mortality rate of an infrarenal
clamp alone equivalent to an endovascular repair?
Dr Francisco Albuquerque: In regards to the adjunctive
treatment, we don’t have the data specifically in this paper. We had
performed endovascular repair in complex anatomy outside IFU,
and we have some preliminary data on our research on secondary
intervention that we intend to publish later. Our service published
a paper in the Journal of Vascular Surgery, I think in May 2008,
about technical notes in Palmaz stent placement, where they had
20 Palmaz stents placed. On our preliminary data from the second-
ary procedure research, I found that at least 15 were done in the2003 to 2008 period for the initial procedure. The other five could
have been done in the first period or later during follow-up.
For the secondary procedures and endoleak rates, we will show the
dataonthesecondaryprocedurepaper. Itwasnot the intentonthiswork.
We also had a paper published in 2002 about secondary procedure, and
the incidence was around 20%. I have preliminary data that show a
probable significant decrease in secondary intervention in the second
periodand ithasbeenaround10%.ThePalmazstentplacementprobably
reflects the type I endoleak at the initial procedure that we dealt with.
In terms of conversion, looking again at the data for secondary
procedure, I found about 14 conversions, 7 at the initial procedure,
and 7 later. But all the 14 conversions were done in the subgroup of
patients that had the endograft placed in the first period. We actually
had one conversion recently, about 3 months ago, that would not be
on that study because it was not done in the study period.
We do not have the data on utilization of endografts in younger
patients. In our institution, we usually offer and perform EVAR if the
patient has a very good anatomy, even in the younger patients. If there is
a questionable good anatomy for EVAR and there is no doubt that the
patient is a good surgical risk, we usually perform an open repair.
Regarding the complexity of open AAA repairs, we did not
look at the different mortality rates for the different levels of aortic
clamping for open repair. We have a very small sample size for
those, and the mortality difference probably would not be statisti-
cally significant. We excluded the patients that required renal artery
reimplantation. I agree that in order to have a “fair” comparison,
we should be comparing the EVAR mortality with the mortality of
the open AAA repair that required infrarenal clamp. I don’t think
that it would be possible to have a randomized trial to compare
EVAR vs open AAA repair in patients with difficult anatomy such
as a very short and/or angulated neck. We may have an answer if
you look at a large registry, like the EUROSTAR [European Col-
laborators on Stent-Graft Techniques for Aortic Aneurysm Repair],
that probably has more than 8,000 to 10,000 patients. I guess that
there are some groups that are performing EVAR with difficult
anatomy outside IFU after they have gone with the pivotal trials.
Dr William Jordan Jr (Birmingham, Ala): First, while I see
your comment here on your last slide about you think some grafts
are better, do you have that much confidence that this is really
related to the better Zenith graft? I know we don’t want to be too
commercial here, but that is one question.
The other question is, consider the training paradigm that you
are in now, I’d like to know how you feel about doing open repair
now when you’re seeing 70%, 80%, and even 90% of your aneu-
rysms done with endo as opposed to open? Do you feel good about
having that open experience?
Dr Albuquerque: I don’t think it is related basically just to
the Zenith device but to the newer endografts with active fixation
and better engineering. The devices with suprarenal fixation may
play a role, but we may have some bias on that. We sometimes treat
type I endoleak with a Palmaz stent that works also with the
principal of suprarenal fixation. It looks intuitive, and it does not
cause a problem with renal perfusion.
I also showed that there was an increase in the utilization of
the Excluder device that does not have suprarenal fixation but it is
part of the newer generation endografts. It has a lower profile and
may be better for certain anatomic configuration such as female
with small iliac arteries.
What was the last question?
Dr Jordan: Your open experience.
Dr Albuquerque: People would say that you should see one,
help one, and do the third one. Maybe the saying is “see one, do one,
and teach one.” I am more conservative. I don’t think it would be
much different if you are doing this, as long as you can still have some
good training on doing more complex AAA repair. It would depend
on the number of those complex cases. I think that you still could have
a good open experience without doing a huge number of open cases.
We also have the aortoiliac occlusive disease where you will be doing
work on the aorta that will help us with the open repair experience.
